ALKBH5 and cancer: Our results showing the induction of the UPR in ALKBH5-silenced cancer cells suggest that inhibiting ALKBH5 may be a novel approach for new drugs to treat cancers that depend on ALKBH5 pro-tumorigenic signaling.